A Randomized Phase II Study of Weekly or Every 3 Weeks ABI-007 Versus Every 3 Weeks Taxotere as First Line Therapy of Stage IV (Metastatic) Breast Cancer.

Trial Profile

A Randomized Phase II Study of Weekly or Every 3 Weeks ABI-007 Versus Every 3 Weeks Taxotere as First Line Therapy of Stage IV (Metastatic) Breast Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jul 2013

At a glance

  • Drugs Docetaxel (Primary) ; Paclitaxel (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 10 Dec 2011 Overall survival and tolerability results presented at the 34th Annual San Antonio Breast Cancer Symposium.
    • 27 Sep 2011 Subgroup analysis results for overall survival presented at the 2011 European Multidisciplinary Cancer Congress.
    • 10 Sep 2011 Final overall survival results presented at the 2011 Breast Cancer Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top